Provider of drugs for the treatment of schizophrenia in adults. The company provides drugs for the treatment of schizophrenia in adults, and for the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults, as monotherapy or as adjunctive therapy with either lithium or valproate.
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
This information is available in the PitchBook Platform. To explore Organon‘s full profile, request access.
Request a free trialName | Title | Board Seat | Contact Info |
---|---|---|---|
Rachel Stahler | Chief Information Officer | ||
Kevin Ali | Chief Executive Officer | ||
Matthew Walsh | Chief Financial Officer |
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|
This information is available in the PitchBook Platform. To explore Organon‘s full profile, request access.
Request a free trial